Finally, the ability of the MB-1 vaccine to elicit both mucosal and humoral immunity is crucial; mucosal immunity (IgA) provides the first line of protection, avoiding infection, while humoral immunity (neutralizing IgY) provides the second line of protection, limiting the time of infection and therefore, improving prognosis [1,3,13]. This evidence concerns the gene CD79A and infection.